Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (24)

Advertisement

Research Article Free access | 10.1172/JCI113819

Urokinase-dependent adhesion loss and shape change after cyclic adenosine monophosphate elevation in cultured rat mesangial cells.

W F Glass 2nd, R A Radnik, J A Garoni, and J I Kreisberg

Department of Pathology, University of Texas, San Antonio 78284.

Find articles by Glass, W. in: JCI | PubMed | Google Scholar

Department of Pathology, University of Texas, San Antonio 78284.

Find articles by Radnik, R. in: JCI | PubMed | Google Scholar

Department of Pathology, University of Texas, San Antonio 78284.

Find articles by Garoni, J. in: JCI | PubMed | Google Scholar

Department of Pathology, University of Texas, San Antonio 78284.

Find articles by Kreisberg, J. in: JCI | PubMed | Google Scholar

Published December 1, 1988 - More info

Published in Volume 82, Issue 6 on December 1, 1988
J Clin Invest. 1988;82(6):1992–2000. https://doi.org/10.1172/JCI113819.
© 1988 The American Society for Clinical Investigation
Published December 1, 1988 - Version history
View PDF
Abstract

Mesangial cells in culture change shape and become less adhesive in response to cAMP elevation (e.g., treatment with isoproterenol plus isobutylmethylxanthine (IM). Inhibitors of serine proteases inhibit cellular shape change in response to IM. To further examine the role of cell surface proteases in shape change, adhesion plaque proteins (i.e., preparations of ventral membranes and extracellular matrix) were separated in SDS-polyacrylamide gels containing gelatin with and without plasminogen. Four discrete zones of lysis were evident in plasminogen gels (indicative of activation of plasminogen) from control adhesion plaques: one inconspicuous zone with a Mr approximately 150 kD, another at approximately 115 kD, and a doublet at approximately 35-32 kD. Another diffuse zone of lysis centered around Mr approximately 70 kD and contained a defined band of approximately 56 kD. Adhesion plaques contained most of the plasminogen activators (PA). 5 min after IM treatment, the Mr approximately 150- and approximately 115-kD PA were increased in activity. Vasopressin (VP), which prevented shape change and adhesion loss when added along with IM, inhibited the increase in these PA. Preincubation with monoclonal or polyclonal antibodies to urokinase-type plasminogen activator (uPA) totally inhibited the IM-inducible shape change and adhesion loss. Activation of plasminogen throughout the gels revealed multiple protease resistant bands that markedly increased with IM treatment (maximal at 45 min). These may represent focal control mechanisms. uPA thus may mediate focal proteolysis, which results in shape change and decreased adhesion.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1992
page 1992
icon of scanned page 1993
page 1993
icon of scanned page 1994
page 1994
icon of scanned page 1995
page 1995
icon of scanned page 1996
page 1996
icon of scanned page 1997
page 1997
icon of scanned page 1998
page 1998
icon of scanned page 1999
page 1999
icon of scanned page 2000
page 2000
Version history
  • Version 1 (December 1, 1988): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (24)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts